Compare AbbVie Inc (ABBV) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance

AbbVie IncTrade

Invesco S&P 500 High Div Low Volatility ETFTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? AbbVie Inc trades at $249.78 (market cap $441.94B), while Invesco S&P 500 High Div Low Volatility ETF trades at $52.5. The key difference: AbbVie Inc pays a 2.77% dividend while Invesco S&P 500 High Div Low Volatility ETF pays none. Which is the better fit depends on your goals.

	ABBV	SPHD
Market Cap	$441.94B	—
Sector	Health	—
52-Week High	$263.58	$53.55
52-Week Low	$197.38	$46.96
Enterprise Value	$506.19B	—
Dividend Yield	2.77%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.

Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.

Invesco S&P 500 High Div Low Volatility ETF

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ABBV

Fidelity Dividend ETF's payout is safe but not ideal for steady income due to variable quarterly dividends.24/7 Wall Street · 23 hours agoNeutral Two Dividend Aristocrats outperformed the market while two lagged; three new picks show promising dividend growth.24/7 Wall Street · 2 days agoNeutral Healthcare sector leads S&P 500 gains over 3 months with key pharma stocks showing strong innovation and income potential.24/7 Wall Street · 2 days agoBullish View details →

SPHD

View details →

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

About Invesco S&P 500 High Div Low Volatility ETF

The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.